Scholars have reported that R-2-hydroxyglutarate (R-2HG) abates FTO/m6A/YTHDF2-mediated upregulation of phosphofructokinase platelet (PFKP) and lactate dehydrogenase B (LDHB) which suppress aerobic glycolysis and exert an anti-tumor effect in R-2HG-sensitive leukemia cells (Qing et al., 2021). The gene discussed is PFKP; the disease is leukemia.